Theravance Biopharma TBPH Receivables From Collaboration Partners
Receivables From Collaboration Partners at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:ReceivablesFromCollaborationPartners.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's receivables from collaboration partners.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's receivables from collaboration partners?
- Theravance Biopharma (TBPH) reported receivables from collaboration partners of $15.58M in Q1 2026.
- How has Theravance Biopharma's receivables from collaboration partners changed year-over-year?
- Theravance Biopharma's receivables from collaboration partners increased by 1.5% year-over-year, from $15.35M to $15.58M.
- What is the long-term trend for Theravance Biopharma's receivables from collaboration partners?
- Over 5 years (2020 to 2025), Theravance Biopharma's receivables from collaboration partners has grown at a 23.5% compound annual growth rate (CAGR), from $15.87M to $45.54M.
- What does receivables from collaboration partners mean?
- This represents the outstanding amounts owed to the company by strategic partners for services rendered or shared costs under collaborative research and development agreements. It reflects the short-term liquidity expected from ongoing partnerships and the company's ability to collect on contractual arrangements. Monitoring this helps assess the reliability of cash inflows from external collaborative activities.